Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension of Paliperidone ER in Schizophrenia
NCT00210769Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Jan 2004
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of paliperidone in schizophrenia, sponsored by Johnson & Johnson. Started Jan 2004; status: completed.
02
Drugs
paliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00210769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00210769.